Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Signs positive for biotech deal activity in 2010

This article was originally published in Scrip

Executive Summary

If the activity seen in late December is anything to go by, 2010 could be a bumper year for deal-making, particularly in biotech. December was a busy month, with a raft of new, mostly biotech-related deals involving big pharma. Companies including Teva, AstraZeneca Pfizer, Lilly and GSK announced deals worth over $2 billion in total.

You may also be interested in...



Siemens Healthineers Adds Muscle To Global Antibody Testing Effort, In Talks With Vaccine Developers

The company now has US emergency use designation for its new SARS-CoV-2 test, which can run on its global installed base of 20,000 analyzers at a current capacity of 50 million tests per month.

Japan Approves Country’s First SARS-CoV-2 Antigen Test Kit As It Aims To Ramp Up Testing Numbers

The test, made by Fujirebio, will help Japan to reach its 400,000-per-week COVID-19 test target.

FDA Grants EUA For Roche’s Coronavirus Antibody Test

The company says the serology test has a specificity of 99.8% and sensitivity of 100%

Topics

Related Companies

UsernamePublicRestriction

Register

CO008261

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel